AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Merck & Co., Inc.
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5TC52
145.60▲ 3.22 (2.26%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
142.38
Day's Range
141.36 – 146.68
52-Week Range
82.01 – 156.92
Volume
8.0M
Avg Volume
8.8M
Share Statistics
Shares Outstanding
Employees
75.0K
Exchange
XNYS
Listed
1949-04-20
Share count as of July 31, 2026

Merck & Co., Inc. (MRK) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Merck & Co., Inc. (MRK)
What is Merck & Co., Inc.'s Market Cap?
Merck & Co., Inc.'s Market Cap is $359.2B, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Enterprise Value?
Merck & Co., Inc.'s Enterprise Value is $406.0B, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Trailing P/E?
Merck & Co., Inc.'s Trailing P/E is 113.2×, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Price / Sales?
Merck & Co., Inc.'s Price / Sales is 5.4×, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s EV / Revenue?
Merck & Co., Inc.'s EV / Revenue is 6.1×, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s EV / EBITDA?
Merck & Co., Inc.'s EV / EBITDA is 29.6×, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Revenue (TTM)?
Merck & Co., Inc.'s Revenue (TTM) is $66.6B, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Net Income (TTM)?
Merck & Co., Inc.'s Net Income (TTM) is $3.2B, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s EBITDA?
Merck & Co., Inc.'s EBITDA is $13.7B, based on as-reported figures from SEC (XBRL) filings.
What is Merck & Co., Inc.'s Diluted EPS (TTM)?
Merck & Co., Inc.'s Diluted EPS (TTM) is 1.29, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MRKAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Sales
YoY growth+5.1%+4.9%+5.0%+3.7%
Costs, Expenses and Other
Cost of sales
Selling, general and administrative
Research and development
Restructuring costs
Other (income) expense, net
Total Costs, Expenses and Other
(Loss) Income Before Taxes
Income Tax Provision
Net (Loss) Income
% of revenue-8.1%-26.1%18.1%33.5%
Less: Net (Loss) Income Attributable to Noncontrolling Interests
Net (Loss) Income Attributable to Merck & Co., Inc.
% of revenue-8.0%-26.0%18.1%33.5%
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)—
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)—